Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02109198

Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)

Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Phase)

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
U.S. Army Medical Research and Development Command · Federal
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the feasibility of combining PoNS therapy with standard vestibular and balance therapy with the proposed double-blind design; evaluate preliminary indications of efficacy. This study is also evaluating recruitment rate, completion rate, device usability, and outcome measures feasibility. * Goal for recruitment: 100% of 30 subjects meeting all inclusion criteria can be recruited over the 36 week pilot recruitment phase. * Completion and compliance: 90% of subjects will complete the study, 90% of sessions within each subject will be completed, and for completing subjects, 100% of measures will be completed. * Useability: all therapists and subjects must rate useability as good or better. * Success of blind: subject accuracy at guessing group membership must be at or near 50%.

Conditions

Interventions

TypeNameDescription
DEVICEActive CN-NINM PoNSDelivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
DEVICESham CN-NINM PoNSDelivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.

Timeline

Start date
2015-06-01
Primary completion
2016-08-01
Completion
2016-08-01
First posted
2014-04-09
Last updated
2015-06-02

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02109198. Inclusion in this directory is not an endorsement.